Found 53 articles for: "Atopic Dermatitis"
Treatment or Trigger? The Use of Biologic Therapy for Alopecia Areata
May 2026 | Volume 25 | Issue 5 | Features | 489 | Copyright © May 2026
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel
March 2026 | Volume 25 | Issue 3 | Original Article | 221 | Copyright © March 2026
Background: Advanced topical nonsteroidal therapies are expanding options for atopic dermatitis (AD) by providing targeted anti-inflammatory control without many limitations of l...
Read MoreFrom Bald to Bold: Reversal of Alopecia Totalis in an Adolescent Using Dupilumab Monotherapy
March 2026 | Volume 25 | Issue 3 | Case Reports | 273 | Copyright © March 2026
Introduction: Alopecia areata (AA) is an autoimmune condition marked by non-scarring, patchy hair loss of the scalp which progresses in <10% of cases to alopecia totalis (AT),...
Read MoreRacial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States
January 2026 | Volume 25 | Issue 1 | Original Article | 54 | Copyright © January 2026
Background: Atopic dermatitis (AD) disproportionately affects diverse patient populations, and complex factors influence access to treatment among different racial and ethnic gro...
Read MoreSAIGE I: Staphylococcus aureus, Immunological, Genetic, and Environmental (SAIGE) Factors Contributing to Atopic Dermatitis and the Use of Ceramide-Containing Skincare
October 2025 | Volume 24 | Issue 10 | Original Article | 1012 | Copyright © October 2025
Background: Atopic dermatitis (AD) is a common heterogeneous disorder that typically starts in infancy and early childhood, is associated with the development of comorbidities, a...
Read MoreSkin Barrier Benefits of a Natural Moisturizing Factor and Lipids-Based Moisturizer for Clinically Sensitive Skin
October 2025 | Volume 24 | Issue 10 | Original Article | 1029 | Copyright © October 2025
Read MoreEvaluating Topical Nitric Oxide Formulations Against an Atopic Dermatitis Methicillin-Resistant S. Aureus Isolate in a Porcine Infection Model
October 2025 | Volume 24 | Issue 10 | Original Article | 1003 | Copyright © October 2025
Background: Atopic dermatitis (AD) is a skin disorder characterized by reduced skin barrier function, which often leads to recurring infections, predominantly by Staphylococcus a...
Read More1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use
October 2025 | Volume 24 | Issue 10 | Original Article | 979 | Copyright © October 2025
Background and Objective: Atopic dermatitis (AD) affects 15% to 20% of children. Evidence supporting the effectiveness of colloidal oatmeal-based moisturizers in improving mild-t...
Read MoreRuxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Original Article | 1036 | Copyright © October 2025
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal...
Read MoreUnderstanding Topical Steroid Withdrawal: Where Are We Now?
October 2025 | Volume 24 | Issue 10 | Features | 1057 | Copyright © October 2025
Beyond Inflammation and Itch: A Call for a Broader Framework in Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Editorials | e62 | Copyright © October 2025
The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review
October 2025 | Volume 24 | Issue 10 | Features | 1054 | Copyright © October 2025
The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment Option
September 2025 | Volume 24 | Issue 9 | Original Article | 920 | Copyright © September 2025
Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by complex interactions among Staphylococcus aureus colonization and ...
Read MoreSAIGE II: The Role of Staphylococcus aureus in Skin Barrier Dysfunction and the Development and Severity of Atopic Dermatitis in Young Children
August 2025 | Volume 24 | Issue 8 | Original Article | 810 | Copyright © August 2025
Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition that often manifests in infancy or early childhood, with significant impacts on quality of life and po...
Read MorePin-Based Fractional Radiofrequency: 2024 International Consensus Recommendations for Aesthetic Skin Indications
August 2025 | Volume 24 | Issue 8 | Original Article | 817 | Copyright © August 2025
Background and Objective: Fractional radiofrequency was developed as a potentially lower-risk and downtime alternative to traditional fractional ablative and nonablative lasers f...
Read MoreTreating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World Experience
July 2025 | Volume 24 | Issue 7 | Features | 702 | Copyright © July 2025
Background: Chronic hand eczema (CHE) is a chronic inflammatory skin condition that affects the hands and wristscausing itching, dryness, cracking, and pain. It ofte...
Read MoreSocioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis: Affordability and Pharmacy Deserts
July 2025 | Volume 24 | Issue 7 | Original Article | 683 | Copyright © July 2025
Background: Gentle skin care is key to atopic dermatitis (AD) treatment, yet products are often expensive. Pharmacy deserts may exacerbate socioeconomic disparities in AD....
Read MorePractical Algorithm on Topical Treatment of Flaring Atopic Dermatitis (AD) With or Without Secondary Infection
June 2025 | Volume 24 | Issue 6 | Original Article | 621 | Copyright © June 2025
Acute exacerbations or flares are a key characteristic of atopic dermatitis (AD), often associated with sleep deprivation, as well as experiences of stigmatization, social withdrawal, anxiety, an...
Read MoreRapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
June 2025 | Volume 24 | Issue 6 | Original Article | 600 | Copyright © June 2025
Background: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in adults and children down to 2 ye...
Read MoreRacial and Ethnic Representation in Atopic Dermatitis Clinical Trials
April 2025 | Volume 24 | Issue 4 | Original Article | 360 | Copyright © April 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
